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Introduction
Parkinson’s disease (PD) is the second most common neurode-
generative disease. It is estimated to affect approximately 6 mil-
lion people worldwide, and its prevalence will increase further 
as populations age (1). Patients with PD suffer debilitating motor 
symptoms as well as nonmotor symptoms including dementia 
and neuropsychiatric abnormalities (2, 3). Dopamine neurons in 
the substantia nigra pars compacta (SNc) and their projections 
into the striatum are especially susceptible to disruption in PD (4). 
Loss and impaired function of dopamine neurons cause the motor 
abnormalities that are a hallmark feature of PD. Although current 
treatments can sometimes relieve PD symptoms, no therapies pre-
vent the neurodegeneration (5).
PD may have a number of different causes, and several patho-
genic mechanisms have been proposed to contribute to the apop-
totic death of neurons (6–10). In the majority of cases, the etiol-
ogies are unknown and probably complex. Aging, environmental 
toxins, and genetic mutations are all risk factors. In many cases, 
energy deficits and decreased ATP levels are observed in PD (11). 
First, aging, the major risk factor for PD, impairs cerebral glucose 
metabolism, reduces mitochondrial biogenesis, and decreases 
ATP levels (12). Second, glycolysis and mitochondrial function 
are decreased in individuals with PD (13, 14). Third, mitochondri-
al toxins (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [MPTP], 
rotenone, paraquat) induce PD and PD-like phenotypes in cells 
and animals, including humans (15). Fourth, mutations associat-
ed with familial PD (e.g., PINK1, LRRK2, α-synuclein, parkin, DJ-1, 
CHCHD2) disrupt various aspects of energy metabolism (16). 
It is also hypothesized that SNc dopaminergic neurons may be 
particularly susceptible to PD neurodegeneration, because their 
highly branched, unmyelinated axonal arbor, their many neu-
rotransmitter release sites, and their rhythmic firing engender a 
large metabolic burden (17). These considerations suggested that 
impaired bioenergetics and reduced ATP levels might contribute 
to the pathogenesis of PD, might modify the risk of developing PD 
in the face of PD risk factors, and/or might modify the course or 
severity of the disease.
We recently discovered that terazosin (TZ) binds and acti-
vates phosphoglycerate kinase 1 (PGK1) (18), the first ATP-gen-
erating enzyme in glycolysis (Figure 1A). TZ is an α1-adrenergic 
receptor antagonist that can relax smooth muscle and is pre-
scribed to treat benign prostatic hyperplasia and, rarely, hyper-
tension (19). However, biochemical and functional studies show 
that the effects of TZ on PGK1 are independent of α1-adrenergic 
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administration of MPTP to mice, pyruvate and ATP levels fell 
(Figure 1, F and G, and Supplemental Figure 2, A–C), and admin-
istration of TZ prevented the fall in pyruvate and ATP levels. Mito-
chondrial content (assessed by the ratio of mitochondrial DNA to 
nuclear DNA and by VDAC and PHB1 levels) also fell (Supplemen-
tal Figure 2, D–F). TZ partially prevented the decrease. As previ-
ously suggested (23), the increased pyruvate levels may have stim-
ulated mitochondrial biogenesis. It would be difficult to measure 
ATP specifically in neurons, however, we observed similar chang-
es in human neuroblastoma cells (Supplemental Figure 3, A–E). 
These data indicate that TZ activates glycolysis in vivo. Together 
with measurements of brain TZ levels (Supplemental Figure 3F), 
they also indicate that TZ readily crosses the blood-brain barrier.
Although PGK1 produces ATP, oxidative phosphorylation is 
probably important for increasing ATP on the basis of the follow-
ing: (a) pyruvate, the product of glycolysis and major substrate for 
the citric acid cycle, increased (Figure 1, C and F, Supplemental 
Figure 1B, Supplemental Figure 2B, and Supplemental Figure 3A); 
(b) citrate synthase activity, a marker of mitochondrial activity, 
increased (Figure 1D, Supplemental Figure 1C, and Supplemental 
Figure 3B); (c) the extracellular acidification rate, a measure of gly-
colysis, and the O2 consumption rate, a measure of mitochondrial 
respiration, both increased (Supplemental Figure 3, D and E); and 
(d) mitochondrial content was partially maintained after MPTP 
(Supplemental Figure 2, D and F), which may have also contribut-
ed to the increased ATP content.
TZ decreases MPTP-induced neurodegeneration in mice. MPTP 
can model aspects of dopamine neuron loss in mice (21). To deter-
mine whether PGK1 stimulation would slow or prevent MPTP- 
mediated deficits, we administered MPTP to the mice, followed 
antagonism (18). The crystal structure of TZ with PGK1 revealed 
that the 2, 4-diamino-6, 7-dimethoxyisoquinazoline motif of TZ 
binds PGK1 adjacent to the ADP/ATP binding site. In cultured 
cells, TZ enhanced PGK1 activity, thereby increasing ATP levels, 
and inhibited apoptosis (18).
The impaired energy production in PD, together with the 
ability of TZ to increase PGK1 activity, led us to hypothesize that 
increasing glycolysis in vivo might slow or prevent the apoptotic 
neurodegeneration of PD. To test this hypothesis, we used mod-
els of PD in flies, mice, rats, and human cells, and we interrogated 
patient databases to learn whether TZ altered the course of disease.
Results
TZ increases brain ATP levels in vivo in mice. To determine whether 
TZ would enhance glycolysis in vivo, we administered the drug to 
mice. TZ increased the levels of pyruvate, the product of glycolysis, 
in the SNc and striatum as well as in cortex (Figure 1, B and C, and 
Supplemental Figure 1, A and B; supplemental material available 
online with this article; https://doi.org/10.1172/JCI129987DS1). 
Increased pyruvate enhances oxidative phosphorylation (20), 
and consistent with this finding, we observed that TZ increased 
citrate synthase activity, a marker of mitochondrial activity (Fig-
ure 1D and Supplemental Figure 1C). Correspondingly, we found 
that ATP levels increased (Figure 1E and Supplemental Figure 1D). 
Like previous in vitro data, the dose response was biphasic; our 
previous studies suggest that, at low but not high concentrations, 
TZ may enhance ATP release from PGK1 (18).
We also asked whether TZ would increase energy production 
in mice that received MPTP. MPTP causes PD in humans and 
is used to model PD in other animals (21, 22). Seven days after 
Figure 1. TZ enhances glycolysis in the mouse brain. Data points represent individual mice. Blue indicates controls and red indicates TZ treatment. (A) 
Schematic of ATP production by glycolysis and oxidative phosphorylation. (B) Schematic time course for experiments in C–G. Eight-week-old C57bl/6 mice 
were given MPTP (20 mg/kg i.p.) or vehicle 4 times at 2-hour intervals. Then, TZ (10 μg/kg) or vehicle was injected i.p. once a day for 1 week. Assays were 
performed on day 7. (C–E) Pyruvate levels (C), citrate synthase (CS) activity (D), and ATP levels (E) were measured in mouse striatum. TZ doses are indicat-
ed in E. n = 6. Statistical comparison was made versus no TZ treatment. (F and G) Pyruvate (F) and ATP (G) levels in the mouse striatal region. Supplemen-
tal Table 3 shows statistical tests and P values for all comparisons. Bars and whiskers indicate the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by 
Mann-Whitney U test (C and D), Kruskal-Wallis with Dunn’s test (E), and Kruskal-Wallis with Dwass-Steele-Critchlow-Fligner test (F and G).
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Figure 4, A and B). As a result, the dopamine, 3,4-dihydroxyphe-
nylacetic acid (DOPAC) and homovanillic acid (HVA) content of 
the striatum and SNc decreased (Figure 2, H and I, and Supple-
mental Figure 4, C–F). MPTP also increased the percentage of 
TH-positive cells that were TUNEL positive, indicating increased 
apoptosis (Figure 2J and Supplemental Figure 4, G and H). Begin-
ning TZ treatment at the time we administered MPTP attenuat-
ed all these defects on day 7. When TZ delivery was delayed for 
7 days after MPTP administration, it improved the abnormalities 
on day 14. Consistent with these biochemical defects, TZ prevent-
ed deficits in motor function on day 7, and it improved motor per-
formance on day 14 after delayed administration (Figure 2K and 
Supplemental Figure 4, I and J).
by administration of TZ for the next 7 days, and an assay on day 7 
(Figure 2A). Because individuals with PD present after the onset of 
neuron degeneration, we also asked whether delayed TZ admin-
istration would slow neuron loss and functional decline. There-
fore, in some mice, we waited 7 days after delivering MPTP before 
starting the 7-day course of TZ treatment. We then performed an 
assay on day 14 (Figure 2A).
Over the course of 14 days, MPTP progressively decreased the 
levels of tyrosine hydroxylase (TH), the rate-limiting enzyme for 
generating dopamine. MPTP decreased TH levels in the SNc and 
striatum, reduced the numbers of TH-positive cells in the SNc, 
and decreased the intensity of TH immunostaining in the neuron 
projections into the striatum (Figure 2, B–G, and Supplemental 
Figure 2. TZ improves dopamine neuron and motor function in MPTP-treated mice. (A) Schematic for experiments in panels B–K. Eight-week-old 
C57BL/6 mice received 4 i.p. injections of MPTP (20 mg/kg at 2-hour intervals) or vehicle on day 0. Mice were then injected with TZ (10 μg/kg) or vehicle 
(0.9% saline) once a day for 1 week, and assays were performed on day 7. Other mice began receiving daily TZ or vehicle injections beginning on day 7, and 
assays were performed on day 14. n = 6. (B–D) Example of Western blots with TH and β-actin (protein loading control) in striatum and SNc on days 7 and 
14 (B). Quantification of TH protein normalized to control (C and D). n = 6. (E) Example of immunostaining of TH in SNc and striatum. Scale bars: 100 μm 
(SNc) and 1 mm (striatum). Quantification of TH-positive neurons in SNc (F) and TH intensity in the striatum (G). n = 6. (H and I) Dopamine (DA) content 
in striatum and SnC. n = 6. (J) Percentage of TH-positive neurons that were positive for TUNEL staining. n = 6. (K) Behavioral response of mice in the 
rotarod test. Data reflect the duration that the mice remained on an accelerated rolling rod, normalized to mice on day 0. n = 8. Data represent examples 
and indicate the mean ± SEM. Blue indicates control and red indicates TZ treatment. *P < 0.05 and **P < 0.01, by Mann-Whitney U test for days 7 and 14. 
Supplemental Table 3 shows P values for all comparisons.
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of TH immunostaining in the striatum also decreased (Figure 3, D 
and E). TZ partially reverted these abnormalities toward control 
values. 6-OHDA progressively decreased dopamine, DOPAC, and 
HVA content, and TZ partially prevented the reduction (Figure 3F 
and Supplemental Figure 5, G and H). Seven weeks after injection 
of 6-OHDA into the right striatum, we observed that use of the left 
forepaw had fallen (Figure 3G), however, when the rats received 
TZ between weeks 5 and 7, they used both forepaws equally.
Previous studies have shown that MPTP and 6-OHDA can 
rapidly reduce TH expression (21), and consistent with this find-
ing, we observed that TH levels, TH-positive neurons, TH intensi-
ty in the striatum, and dopamine content decreased rapidly after 
administration of MPTP and 6-OHDA to mice and rats, respec-
tively (Figures 2 and 3 and Supplemental Figures 4 and 5). Cell 
death was also apparent. However, not all the damaged cells were 
rapidly killed, as cell death continued to progress for at least 14 
days in MPTP-treated mice and for 7 weeks in 6-OHDA–treated 
rats (Figure 2J and Figure 3B). Accordingly, TH levels, TH-positive 
These in vivo results in mice suggest that TZ slows or prevents 
MPTP-induced neurodegeneration, partially restores TH and 
dopamine levels, and improves motor function.
TZ enhancement of PGK1 activity slows neurodegeneration 
in 6-OHDA–treated rats. The compound 6-hydroxydopamine 
(6-OHDA) is delivered to rats to produce a model of dopamine 
neuron degeneration in PD (24). Previous studies have shown pro-
gressive cell death and injury between 2 and 12 weeks after admin-
istration of 6-OHDA (25–27). Therefore, we chose a 7-week course 
of observation. We injected 6-OHDA into the right striatum of 
rats, waited 2–5 weeks, and then initiated a 2-week course of TZ 
treatment (Figure 3A). In vehicle-treated rats, evidence of SNc cell 
apoptosis progressively increased from 2 to 7 weeks (Figure 3B and 
Supplemental Figure 5, A and B). However, irrespective of the delay 
before the start of treatment, we observed that TZ attenuated fur-
ther cell loss. 6-OHDA also progressively decreased TH levels in 
the striatum and SNc (Figure 3C and Supplemental Figure 5, C–F). 
The percentage of TH-positive cells in the SNc and the intensity 
Figure 3. TZ slows neurodegeneration, increases dopamine, 
and improves motor performance in 6-OHDA–treated rats. 
(A) Schematic for experiments in B–G. 6-OHDA (20 μg) was 
injected into the right striatum of rats on day 0. TZ (70 μg/
kg) or saline was injected i.p. daily for 2 weeks, beginning 2, 3, 
4, or 5 weeks after 6-OHDA injection. Assays were performed 
at 0 and 2–7 weeks. (B) Percentage of TUNEL-positive SNc 
cells. n = 6. (C) Quantification of TH protein levels assessed 
by immunoblotting in the striatum, normalized to control. n = 
6. (D and E) Percentage of SNc cells positive for TH immuno-
staining (D) and intensity of TH immunostaining in striatum 
(E) 7 weeks after 6-OHDA injection. TZ treatment was admin-
istered from week 5 to week 7. n = 6. (F) Dopamine content in 
the right striatum relative to the left (control) striatum. n = 6. 
(G) Results of the cylinder test. 6-OHDA was injected into the 
right striatum, impairing use of the left paw. The assay was 
performed 7 weeks after 6-OHDA injection. TZ treatment was 
given from week 5 to week 7. n = 4 for control group and  
n = 10 for the two 6-OHDA groups. In C, D, E, and G, data 
points represent individual rats, and bars and whiskers 
indicate the mean ± SEM. Blue indicates controls and red indi-
cates TZ treatment. Supplemental Table 3 shows statistical 
tests and P values for all comparisons. *P < 0.05, **P < 0.01, 
and ***P < 0.001, by Mann-Whitney U test (B and F), Kruskal- 
Wallis with Dwass-Steele-Critchlow-Fligner test (C, D, and E), 
and Friedman with Dunn’s test (G).
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together with rotenone minimized decrements in ATP content 
and motor performance.
Previous studies showed that TZ increases ATP by enhanc-
ing PGK1 activity (18, 30). We knocked down Pgk in Drosophila by 
expressing RNAi and found that it abolished the protective effect 
of TZ on motor performance (Figure 4, D and E, vs. Figure 4C). 
Conversely, overexpression of PGK1 in Drosophila TH neurons, all 
neurons (Appl promoter), or all cells (actin promoter) made flies 
resistant to rotenone-induced behavioral defects (Figure 4F). In 
contrast, we found that expression in muscle was not protective. 
These results, together with earlier findings (18, 30), indicate that 
TZ protects TH neurons by activating PGK1.
TZ attenuates neurodegeneration in genetic models of PD. In 
addition to toxin-induced models, we tested fly, mouse, and 
human genetic models of PD. PINK1 mutations cause PD in 
humans; we therefore tested the Drosophila PINK15 mutant (31–
33). We administered vehicle or TZ from day 1 after hatching to 
day 10. On day 10, nearly all PINK15 flies exhibited wing posture 
defects (Figure 5A). TZ partially reversed this abnormality. Brain 
TH and ATP levels also decreased, and motor performance was 
impaired in PINK15 flies (Figure 5, B–E, and Supplemental Fig-
ure 6). TZ partially corrected these defects. We also tested the 
Drosophila LRRKex1 mutant (34); LRRK2 mutations cause auto-
somal-dominant, late-onset PD (35). TZ also attenuated motor 
deficits in that model (Figure 5F).
neurons, TH intensity in the striatum, and dopamine content also 
continued to decrease further with time. Administration of TZ, 
even after the onset of neurodegeneration, slowed cell death, and 
it increased TH levels, dopamine content, and motor performance 
compared with vehicle-treated controls (Figures 2 and 3 and Sup-
plemental Figures 4 and 5).
After MPTP and 6-OHDA administration, apoptotic cell 
death continued for 14 days and 7 weeks, respectively. Delayed 
TZ administration (beginning on day 7 in MPTP-treated mice and 
in week 5 in 6-OHDA–treated rats) slowed or prevented further 
apoptotic cell death. In MPTP-treated mice, dopamine levels, 
behavioral performance, and in some cases TH levels on day 14 
exceeded those on day 7. Likewise, in 6-OHDA–treated rats, dopa-
mine and TH levels by week 7 exceeded those in week 5. PD neu-
rons that have not yet undergone apoptotic cell death almost cer-
tainly have impaired metabolic function (28). Our results suggest 
that TZ improved the function of neurons that were impaired by 
MPTP and 6-OHDA but had not yet degenerated.
TZ enhances PGK activity to attenuate rotenone-induced neu-
rodegeneration in flies. As an additional model of PD, we treated 
Drosophila melanogaster with rotenone, a mitochondrial complex 
I inhibitor implicated in sporadic PD (29). Rotenone exposure 
reduced brain ATP levels (Figure 4, A and B). It also disrupted 
motor function as tested by climbing behavior (Figure 4C). PGK 
is highly conserved in flies and mammals, and supplying TZ 
Figure 4. TZ enhances Pgk activity to attenuate rotenone-impaired motor performance. (A) Schematic for experiments in panels B –F. Flies received 
rotenone (125 or 250 μM in food) with TZ (1 μM) or vehicle for 7 or 14 days. (B) Relative ATP content in the brains of w1118 flies that received 250 μM rotenone 
with or without TZ for 14 days. n = 6, with 200 fly heads for each treatment in each trial. (C) Climbing behavior of flies after 250 μM rotenone with TZ (1 
μM) or vehicle for 7 days. Data show the percentage of flies that climbed up a tube (see Methods). n = 3, with 200 flies tested for each treatment in each 
trial. (D) Knockdown of Pgk in offspring of actin-Gal4 crossed with UAS-Pgk RNAi flies. Offspring of actin-Gal4 crossed with y1 v1 P [CaryP] attP2 were 
used as a genetic background matched control. n = 3, with RNA collected from 30 fly heads for each sample. (E) Pgk was knocked down in TH neurons by 
crossing UAS-Pgk RNAi flies with flies carrying the TH neuron-specific promoter (TH-Gal4) to produce TH>Pgk RNAi flies. Rotenone (250 μM) and TZ were 
administered as indicated for 7 days. Climbing behavior was measured on day 7. n = 8, with 200 flies tested for each treatment in each trial. (F) Pgk (UAS-
Pgk) overexpression was driven by a dopaminergic neuron promoter (TH-Gal4), a pan-neuronal promoter (Appl-Gal4), a pan-cell promoter (Actin-Gal4), and 
a muscle-specific promoter (Mhc-Gal4). Rotenone (250 μM) was administered for 7 days, and climbing behavior was measured on day 7. n = 3, with 200 
flies tested for each treatment in each trial. Data points represent individual groups of flies, and bars and whiskers show the mean ± SEM. Blue indicates 
controls and red indicates TZ treatment. Supplemental Table 3 shows statistical tests and P values for all comparisons. *P < 0.05, **P < 0.01, and ***P < 
0.001, by Kruskal-Wallis with a Dwass-Steele-Critchlow-Fligner test (B), 1-way ANOVA with Tukey’s test (C and E), paired t test (D), and unpaired t test (F).
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Abnormal accumulation of α-synuclein, a major constituent of 
Lewy bodies, is a key feature of PD (36). Transgenic mice overex-
pressing WT human α-synuclein (mThy1-hSNCA) exhibit PD-like 
neurodegeneration at an advanced age (37). We began treating 
mThy1-hSNCA mice at 3 months of age with vehicle or TZ. When 
they were 15 months old, the vehicle-treated mice had substantial 
expression of human α-synuclein in the striatum and SNc (Figure 
5, G–J) and impaired motor performance on the rotarod and pole 
tests (Figure 5K and Supplemental Figure 7). TZ treatment partial-
ly prevented these abnormalities.
We also tested the effect of TZ on dopamine neurons differen-
tiated from induced pluripotent stem cells (iPSCs). LRRK2G2019S is 
the most common LRRK2 mutation and is associated with approx-
imately 4% of familial PD cases and approximately 1% of sporadic 
PD cases (38). Dopamine neurons derived from LRRK2G2019S iPSCs 
recapitulate PD features including abnormal α-synuclein accumu-
lation (39). We studied such neurons generated from 2 patients. 
After 30 days of differentiation, the dopamine neurons showed no 
overt signs of neurodegeneration (Supplemental Figure 8). How-
ever, approximately 60% of the LRRK2G2019S dopamine neurons 
had accumulated α-synuclein compared with approximately 15% 
of dopamine neurons from healthy individuals (Figure 6, A and 
B). Addition of TZ for 24 hours increased the ATP content and 
reduced the percentage of LRRK2G2019S dopamine neurons with 
elevated α-synuclein accumulation (Figure 6, A–C).
In the Parkinson’s Progression Markers Initiative database, indi-
viduals with PD who were taking TZ had a reduced rate of progres-
sive motor disability. In the past, assessment of whether an agent 
might affect PD has been largely limited to animal models. Three 
factors allowed us to assess efficacy in humans. First, TZ is a rela-
tively commonly used drug. Second, availability of human clinical 
databases allowed us to test for a TZ effect. Third, tamsulosin can 
serve as a control for TZ. Like TZ, tamsulosin is an α1-adrenergic 
antagonist, and, like TZ, tamsulosin is prescribed for benign pros-
Figure 5. TZ improves TH levels and motor performance in genetic models of PD. Data points are from individual mice and groups of flies. (A–E) WT 
(w1118) and PINK15 flies received TZ or vehicle for 10 days beginning on the first day after eclosion. Day 10 assays included: (A) Example of wing posture 
defect and percentage of w1118 and PINK15 flies with wing posture defects. n = 6, with 80 flies for each treatment in each trial. (B and C) Example of TH 
Western blot (B) and quantification of TH (C). n = 5, with 40 fly heads for each treatment in each trial. (D) ATP content in brains (relative to w1118). n = 3, 
with 200 fly heads for each treatment in each trial. (E) Climbing behavior of flies. n = 3, with 100 flies for each treatment in each trial. (F) Climbing behav-
ior of LRRKex1 male flies. n = 6, with 100 flies for each treatment in each trial. (G–K) TZ administration to mThy1-hSNCA–transgenic mice. (G) Schematic 
for experiments in panels H–K. (H) Example of Western blot of α-synuclein in striatum and SNc. (I and J) Quantification of α-synuclein in striatum and 
SNc. n = 5. (K) Duration that mice remained on an accelerating rotarod. n = 5. Data are from individual groups of flies (A–F) and individual mice (I–K). 
Bars and whiskers indicate the mean ± SEM. Blue indicates controls and red indicates TZ treatment. Supplemental Table 3 shows statistical tests and 
P values for all comparisons. *P < 0.05, **P < 0.01, and ***P < 0.001, by 1-way ANOVA with Tukey’s test (D) and Kruskal-Wallis with a Dwass-Steele-
Critchlow-Fligner test (A–C, E, F, and I–K).
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
4 5 4 5jci.org   Volume 129   Number 10   October 2019
tatic hyperplasia. However, in contrast to TZ, tamsulosin does not 
have a quinazoline motif that binds to and enhances PGK1 activity.
PD is common in older men, its incidence increases mark-
edly after age 60, and the prevalence of the disease in men is 
approximately 1.5 times that in women (40). TZ is prescribed for 
benign prostatic hyperplasia, a disease that also affects older men. 
Therefore, we suspected that some patients with PD used TZ, and 
we hypothesized that they would have a reduced rate of disease 
progression. To test this hypothesis, we interrogated the Parkin-
son’s Progression Markers Initiative (PPMI) database. This data-
base enrolls patients with PD shortly after diagnosis and follows 
their motor function as determined by the Movement Disorder 
Society’s Unified Parkinson’s Disease Rating Scale Part 3 (41). 
Although this clinical database is small, it is relatively unique in 
assessing motor progression. We identified 7 men with PD who 
used TZ and compared them with 269 men not taking TZ. Com-
pared with the controls, the patients who used TZ had a slower 
rate of motor function decline (Table 1). Although the difference 
was statistically significant, only 7 patients used TZ. We therefore 
sought a larger sample.
The crystal structure of TZ with PGK1 (18) suggested that 
related drugs with quinazoline motifs might also enhance PGK1 
activity. Consistent with that possibility, doxazosin (DZ) and alfu-
zosin (AZ) increased glycolysis in M17 cells and tyrosine hydrox-
ylase levels in MPTP-treated mice (Supplemental Figure 9, A and 
B). We identified 13 men in the PPMI database who were using 
TZ, DZ, or AZ (TZ/DZ/AZ) (Table 1). The progression of motor 
disability was slowed in those patients (Figure 7, Supplemental 
Figure 10, and Table 1).
In contrast to TZ, DZ, and AZ, tamsulosin lacks a quinazo-
line motif for binding to PGK1. Consistent with that, tamsulosin 
did not rescue tyrosine hydroxylase levels in MPTP-treated mice 
(Supplemental Figure 9B). Correspondingly, tamsulosin failed to 
slow the motor function decline of patients enrolled in the PPMI 
database (Figure 7 and Table 1). These data are also consistent 
with the conclusion that enhanced glycolytic activity and attenua-
tion of cell death are mediated by the effect of TZ on PGK1 and not 
on α1-adrenergic receptors.
The IBM Watson/Truven database shows that individuals with 
PD who used TZ/DZ/AZ had fewer PD-related diagnoses. To evalu-
ate a larger number of individuals with PD and to use a different 
database and assessment methods, we interrogated the IBM Wat-
son/Truven Health Analytics MarketScan Database for the years 
2011 to 2016. The database includes longitudinal, deidentified 
diagnoses (ICD-9/ICD-10 codes) and pharmaceutical claims. We 
identified 2880 PD patients with PD taking TZ/DZ/AZ (4821 per-
son years) (Table 2). For a comparison group, we chose patients 
with PD who were taking tamsulosin, which controlled for use of 
an α1-adrenergic antagonist and for the presence of benign pros-
tatic hyperplasia. We identified 15,409 individuals with PD who 
were taking tamsulosin (21,409 person years). To obtain a list of 
diagnostic codes associated with PD, we first identified the 497 
most common diagnostic codes in the group of individuals with 
PD. Then, 2 neurologists who care for patients with PD identified 
79 potentially PD-related diagnoses (Supplemental Table 1).
Using a quasi-Poisson generalized linear model, we found that 
the relative risk (RR) of having any of the 79 PD-related diagnos-
tic codes was 0.78 (95% CI: 0.74–0.82) for the TZ/DZ/AZ group 
relative to the individuals on tamsulosin (P < 0.00001). Of the 
79 PD-related codes, we found a reduced risk in 69 codes among 
patients with PD who were taking TZ/DZ/AZ versus those taking 
tamsulosin (Figure 8A). Moreover, 41 diagnostic codes were sta-
tistically significantly decreased in the PD patients taking TZ/DZ/
Figure 6. TZ increases ATP content and decreases α-synuclein accumu-
lation in iPSC-derived dopamine neurons from patients with PD. (A) 
iPSC-derived dopamine neurons from 2 patients with PD (subjects 12 and 
13) carrying LRRK2G2019S mutations and a healthy control (subject 11). Thirty-
day-old dopamine neurons were plated and were treated with TZ (10 μM) 1 
or 3 days later. The neurons were studied 24 hours after addition of TZ. We 
observed no difference between the 2 start dates and therefore combined 
the data. Representative immunofluorescence images of α-synuclein 
(SNCA, green), TH (red), and DAPI (nuclei, blue). (B) Percentage of TH- 
positive neurons with cytoplasmic accumulation of α-synuclein. n = 12. (C) 
ATP content in control and LRRK2G2019S iPSC–derived dopamine neurons. n = 
12. Bars and whiskers indicate the mean ± SEM. Blue indicates controls and 
red indicates TZ treatment. Supplemental Table 3 shows statistical tests 
and P values for all comparisons. *P < 0.05, **P < 0.01, and ***P < 0.001, by 
Mann-Whitney U test.
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developed PD. The HR from the Cox 
proportional hazards regression for 
the matched cohort was 0.62 (95% 
CI: 0.49–0.78; P < 0.0001).
Discussion
Our results indicate that in both 
toxin-induced and genetic models 
of PD in multiple animal species, 
enhancement of PGK1 activity slows 
or prevents neurodegeneration in 
vivo, thereby increasing dopamine 
levels and improving motor per-
formance. Enhancement of PGK1 
activity showed beneficial effects, 
even when begun after the onset 
of neurodegeneration. Moreover, 
interrogation of 2 independent data-
bases suggested that TZ and related 
quinazoline agents slowed disease 
progression, reduced PD-related 
complications in individuals with PD, and reduced the risk of 
receiving a PD diagnosis.
Evidence from our present and earlier experiments indicates 
that TZ elicits its beneficial effects in PD by enhancing the activity 
of PGK1 and not by inhibiting the α1-adrenergic receptor. Our ear-
lier experiments and crystal structure showed that the quinazo-
line motif of TZ binds PGK1 near the nucleotide binding site (18). 
Studies with recombinant PGK1, studies using cultured cells, and 
measurements in brain following in vivo delivery all revealed a 
biphasic relationship between the concentration of TZ and ATP 
levels (18). In the present study, tamsulosin inhibited α1-adrener-
gic receptors, but its structure lacks a quinazoline group that binds 
PGK1, and it did not enhance glycolysis or prevent the reduction 
of tyrosine hydroxylase levels in MPTP-treated mice. In contrast, 
2 drugs that have a structure similar to that of TZ (DZ and AZ) 
enhanced glycolysis in vitro and protected MPTP-treated mice. 
AZ versus those on tamsulosin, whereas only 2 diagnostic codes 
were significantly increased in the TZ/DZ/AZ group.
To estimate PD-related benefits and risks attributable to TZ/
DZ/AZ versus tamsulosin, we calculated the RR for clinically rel-
evant groupings of the 79 PD-related codes. Relative to patients 
with PD taking tamsulosin, those on TZ/DZ/AZ had reduced 
clinic and hospital visits for motor symptoms (RR 0.77; 95% CI: 
0.70–0.84), nonmotor symptoms (RR 0.78; 95% CI: 0.73–0.83), 
and PD complications (RR 0.76; 95% CI: 0.71–0.82) (Figure 8B, 
Supplemental Table 1, and Supplemental Table 2). Of note, dopa-
mine analogs do not treat PD symptoms such as dementia and 
neuropsychiatric manifestations (3). However, the RR for these 
diagnostic codes was also less than 1.0.
These data suggest that under real-world conditions, TZ and 
related drugs that enhance PGK1 activity reduce PD signs, symp-
toms, and complications.
Individuals who used TZ/DZ/AZ had a decreased risk of PD diag-
nosis. We also used the Truven database to test whether TZ/DZ/
AZ might reduce the frequency of PD diagnoses. We identified 
78,444 PD-free enrollees who were taking TZ/DZ/AZ. During a 
follow-up duration of 284 ± 382 days (mean ± SD), a total of 118 
individuals (0.15%) developed PD. In contrast, in an equal-sized 
cohort of PD-free enrollees taking tamsulosin and matched for age 
and follow-up duration (284 ± 381 days), 190 individuals (0.25%) 
Table 1. Subjects from the PPMI database
Controls Tamsulosin TZ TZ/DZ/AZ
Number of PD patients 269 24 7 13
Dosage mg/d, mean ± SD NA 0.4 ± 0.1 5.0 ± 2.5 TZ 5.0 ± 2.5  
DZ 3.3 ± 1.2  
AZ 10.0 ± 0.0
MDS-UPDRS Part 3 Baseline score,  
mean ± SD
20.2 ± 9.4 20.3 ± 7.1 19.1 ± 12.8 20.9 ± 12.2
P (vs. controls) NA 0.961 0.771 0.81
MDS-UPDRS Part 3 Slope of change/month,  
mean ± SEM
0.54 ± 0.05 0.39 ± 0.14 0.01 ± 0.25 0.02 ± 0.20
P (vs. controls) NA 0.301 0.038 0.013
TZ/DZ/AZ includes patients with PD taking TZ (n = 7), DZ (n = 3), or AZ (n = 3). When comparing TZ with 
controls, the 6 participants taking DZ and AZ were removed (as opposed to being considered part of the 
control group). Statistical analysis was performed using linear mixed-effects regression and is further 
described in the Supplemental Methods. MDS-UPDRS scores were obtained when the participants were not 
yet taking a PD medication or were in the practically defined OFF state (at least 6 hours after the last dose of 
levodopa or any other anti-PD medication).
 
Figure 7. TZ and related drugs slow the progression of motor defects 
for patients with PD enrolled in the PPMI database. Movement Disorder 
Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part 3 
(motor) scores for patients with PD in the PPMI database. Patients were 
taking TZ/DZ/AZ (blue, n = 13), tamsulosin (green, n = 24), or none of 
these drugs (red, n = 269). Data represent scores upon entry into the PPMI 
database through approximately 1 year and include all measures between 
those times. All patients taking these drugs were men prescribed TZ/
DZ/AZ or tamsulosin, without breaks for benign prostatic hyperplasia or 
undefined urological problems. Lines are plotted from linear mixed- 
effect regression analyses. By maximum likelihood estimation, TZ/DZ/AZ 
differed from controls (P = 0.012).
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This study also has limitations, includ-
ing those for toxin-induced and genetic 
models of PD (46). Toxins such as MPTP 
and rotenone can cause PD in humans and 
PD-like disease in animals. Genetic defects 
also cause PD in humans and PD-like dis-
ease in animals. However, most PD is age 
related, with etiologies that remain uniden-
tified and are likely complex. Moreover, no 
current model unequivocally or accurately 
predicts therapeutic benefit or pathogene-
sis. It is precisely for these reasons that we 
used multiple animal models of PD and 
that we sought out human data. A second 
limitation is that our analysis of human 
databases was limited to men, because 
they are treated for benign prostatic hyperplasia. However, we 
expect that similar results would be obtained in women. Third, our 
data from humans are retrospective; however, these data provide 
compelling evidence that cannot be obtained from animal models 
alone. Fourth, our analysis of the PPMI and Truven databases com-
pared patients on TZ/DZ/AZ with those on tamsulosin. Although 
all the drugs were prescribed for benign prostatic hyperplasia, we 
cannot exclude the possibility that some other factor might have 
influenced prescribing behavior. For example, orthostatic hypo-
tension is a complication of both the autonomic dysfunction in PD 
and of the drugs, and there are reports suggesting that tamsulosin 
may elicit less orthostatic hypotension than TZ (47). However, 
such an effect would not explain the PPMI conclusions. Interest-
ingly, the risk of orthostatic hypotension and falls was reduced, not 
increased, for patients with PD taking TZ/DZ/AZ versus those on 
Knockdown of Pgk1 in Drosophila TH neurons abolished the pro-
tective effect of TZ. Overexpression of PGK1 in flies, mice, and 
fish phenocopied the effects of TZ (18, 30). TZ was active in Dro-
sophila melanogaster, which do not have α1-adrenergic receptors. 
Allosteric and covalent regulatory mechanisms have been identi-
fied for most glycolytic enzymes. For example, insulin-stimulated 
deacetylation increases PGK1 activity, and disrupting that regula-
tion results in glycolytic insufficiency (42).
Previous work has identified numerous genetic mutations and 
several environmental factors that cause or predispose individuals 
to PD (11–16, 43). As indicated above, reduced energy metabolism 
and decreased ATP levels are a feature of many of these environ-
mental and genetic factors, as is aging, the major PD risk factor. 
Therefore, enhancing glycolysis might slow progression in PD of 
several etiologies.
This study does not reveal how enhanced glycolysis slows neu-
rodegeneration and progression in PD. However, the increased 
ATP levels produced by TZ may be key. ATP has properties of a 
hydrotrope; it can prevent aggregate formation and dissolve previ-
ously formed protein aggregates (44, 45). Moreover, the transition 
between aggregate stability and dissolution occurs in a narrow 
range at physiological ATP concentrations. We speculate that by 
elevating ATP levels, TZ facilitates the solubilization of aggre-
gates, including α-synuclein, and prevents the neurodegeneration 
of PD. However, other mechanisms are also possible including 
ATP-dependent disaggregases and chaperones (such as hsp90) 
that reduce apoptosis (18, 44, 45).
Table 2. Subjects from the Truven MarketScan database
Tamsulosin TZ DZ AZ TZ/DZ/AZ
Number of enrollees 15,409 1173 1177 529 2879
Person-years of exposure 21,409 2046 1967 808 4821
Dosage mg/d, mean ± SD 0.4 ± 0.0 4.6 ± 3.1 3.9 ± 2.3 10 NA
Age (yr)
Mean ± SD 77.2 ± 7.7 77.8 ± 7.4 77.6 ± 7.7 75.9 ± 8.0 77.4 ± 7.7
Summary of the number of enrollees, duration of exposure, and dose of drugs. Age refers to the age 
of the patient at the first observed medication-dispensing event. The first event can be the age of 
a patient at the time of a refill of a prescription that was begun prior to entry of the patient into the 
Truven database, or it can be the age at which the patient started the medication during the Truven 
observation period. 
Figure 8. TZ and related drugs reduce symptoms as assessed by diag-
nostic codes for patients with PD in the Truven/IBM Watson clinical 
database. Data are from the Truven Health Marketscan Commercial 
Claims and Encounters and Medicare Supplemental Databases for the 
years 2011–2016. Patients had a diagnosis of PD and were prescribed TZ/
DZ/AZ or tamsulosin for at least 1 year. We assessed RRs for 79 previ-
ously identified PD-related diagnostic codes. (A) RR for 79 PD-related 
diagnostic codes for patients taking TZ/DZ/AZ versus tamsulosin. Yellow 
indicates a statistically significant difference in risk between TZ/DZ/
AZ and tamsulosin (P < 0.05) determined by a generalized linear model 
with a quasi-Poisson distribution. (B) RR for the categories of PD-related 
diagnostic codes for patients taking TZ/DZ/AZ versus tamsulosin. Data 
represent the mean and 95% CIs.
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groups of flies also fit a Gaussian distribution. Therefore, parametric 
tests were used to evaluate statistical significance in studies using 
flies, and ANOVA evaluations were 1 way. All statistical tests were 2 
tailed. A P value of less than 0.05 was considered statistically signifi-
cant. Supplemental Table 3 shows the statistical tests used for all data 
and the resulting P values for comparisons.
Study approval. All experiments using mice and rats were approved 
by the IACUC of Peking University in Beijing (approval nos. LSC- 
Liul-1 and LSC-Liul-2).
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tamsulosin. In PD, neurons that have not yet degenerated almost 
certainly have compromised cellular function (28), and we specu-
late that TZ/DZ/AZ improved their functional integrity.
Results from this study, together with earlier data, led us to 3 
additional speculations. First, TZ is already used clinically, and in 
this regard, it is interesting that several studies reported that TZ 
improved glucose metabolism in patients with diabetes (48, 49). 
That observation has gone unexplained. We speculate that stim-
ulation of PGK1 activity might have been responsible. Consistent 
with that conjecture and with the conclusion that an α1-adrener-
gic receptor antagonistic effect was not responsible, we found 
that α1-adrenergic receptor antagonists structurally unrelated to 
TZ lacked that effect. In addition, disruption of the α1B-adrener-
gic receptor in mice had an effect opposite of that induced by TZ 
(50). Second, loss-of-function PGK1 mutations cause recessive 
hemolytic anemia, myopathy, seizures, and intellectual disability. 
However, other studies have reported Parkinsonism (51, 52), and 
the authors speculated that reduced ATP generation in the SNc 
may have been responsible. Third, PD occurs approximately 1.5 
times more frequently in men than in women (53). Why males are 
more predisposed to PD is unknown. However, it may be worth 
noting that the PGK1 gene is located on the X chromosome. Thus, 
the consequences of DNA sequence variations that could subtly 
reduce PGK1 levels or activity might more often manifest in men 
than in women.
Our findings that TZ increased glycolysis and prevented pro-
gressive neurodegeneration suggest that energy deficits might 
either be a pathogenic factor in the pathogenesis of PD or predis-
pose individuals to PD in the presence of environmental or genetic 
etiologies (11, 16). These findings identify a protein and a pathway 
that might be targeted to slow or prevent neurodegeneration in 
PD and potentially other neurodegenerative diseases with altered 
energy balance (54).
Methods
The Supplemental Methods contain information on the materials, 
reagents, experimental procedures, and analysis methods used in 
this study.
Statistics. For experiments to quantify animal behavior and for 
sample collections, the experimenters were blinded to the genotype 
and intervention, and the studies were conducted by 2 different exper-
imenters. The number of animals studied was based on our past expe-
rience and preliminary data. In all figures, data points are from indi-
vidual mice and rats or groups of flies. We did not exclude any data 
points from this study. Data in the figures indicate the mean ± SEM. 
Blue indicates controls, and red indicates TZ treatment. Statistical sig-
nificance for comparisons between data sets was primarily done with 
nonparametric tests. For studies of fly motor performance, our previ-
ous studies showed that within a group of flies (15–50 flies for 1 data 
point), the data fit a Gaussian distribution. Moreover, data for multiple 
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